Related Experiment Video
Updated: Aug 13, 2025
Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
Published on: January 12, 2020
SLC11A2: a promising biomarker and therapeutic target in ovarian cancer
Liming Tian1,2, Xuemei Li3, Huiling Lai1,4
1Department of Gynecology, The First Affiliated Hospital, Sun Yat-Sen University, No. 58, Zhongshan Road II, Guangzhou, 510080, China.
Abstract:
Ovarian cancer has the highest mortality rate among gynecologic tumors, with a 5-year survival rate of less than 25%. There is an urgent need for early diagnosis and new drugs to reduce the disease burden of ovarian cancer. The aim of this study was to investigate the effectiveness of SLC11A2 as a therapeutic target and marker for ovarian cancer. Expression data of SLC11A2 were obtained from public databases. Then, the biological functions of SLC11A2 were validated in four ovarian cancer cell lines. Finally, we collected ovarian cancer clinical tissues, serum, and plasma exosomes and used immunohistochemistry, Elisa, and liquid chromatography-mass spectrometry (LC-MS) to validate the test efficacy of SLC11A2. The results showed that ovarian cancers with high SLC11A2 mRNA expression had shorter 5-year PFS and MST. Knockdown of SLC11A2 reduced ovarian cancer migration and increased cisplatin-induced apoptosis. Serum SLC11A2 may help improve the detection rate of ovarian cancer.
Insights
Solute carrier family 11 member A2 (SLC11A2) shows promise as a therapeutic target and diagnostic marker for ovarian cancer. Targeting SLC11A2 may reduce tumor migration and enhance chemotherapy effectiveness, improving patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Ovarian cancer presents a high mortality rate with limited therapeutic options.
- Early diagnosis and novel drug development are critical for improving survival rates.
- The solute carrier family 11 member A2 (SLC11A2) protein's role in ovarian cancer requires further investigation.
Purpose of the Study:
- To evaluate SLC11A2 as a potential therapeutic target and diagnostic biomarker in ovarian cancer.
- To investigate the functional role of SLC11A2 in ovarian cancer cell behavior.
- To assess the clinical utility of serum SLC11A2 for ovarian cancer detection.
Main Methods:
- Analysis of SLC11A2 expression data from public databases and ovarian cancer cell lines.
- In vitro experiments involving SLC11A2 knockdown in ovarian cancer cells.
- Immunohistochemistry, ELISA, and liquid chromatography-mass spectrometry (LC-MS) on clinical tissues, serum, and exosomes.
Main Results:
- High SLC11A2 mRNA expression correlated with shorter 5-year progression-free survival (PFS) and median survival time (MST).
- SLC11A2 knockdown inhibited ovarian cancer cell migration and increased sensitivity to cisplatin-induced apoptosis.
- Serum SLC11A2 levels showed potential for improving ovarian cancer detection rates.
Conclusions:
- SLC11A2 is a potential therapeutic target that influences ovarian cancer progression and chemoresistance.
- SLC11A2 serves as a promising biomarker for early detection of ovarian cancer.
- Targeting SLC11A2 offers a potential strategy for novel ovarian cancer therapies.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:39lncRNA - Long Non-coding RNAs